Further Boost for Europe’s Largest Healthcare Partnership
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced the launch of IMI2, with a budget of €3.3 billion (US$ 4.5 bn).
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced the launch of IMI2, with a budget of €3.3 billion (US$ 4.5 bn).
IMI (the Innovative Medicines Initiative) is a public-private partnership (PPP) between the European Commission and EFPIA, and was already the largest healthcare PPP in Europe. The budget for its first phase (2008-2013) was €2 bn (US$2.7 bn).
So far, IMI projects have shown a positive impact on research and development: the NEWMEDS project has created the largest known database of studies on schizophrenia; the New Drugs for Bad Bugs Programme has launched project to tackle the growing threat of anti-microbial resistance; and the eTox project is developing a drug safety database based on both industry and public toxicology data, in a step towards greater safety for patients.
The
IMI2 Strategic Research Agendawas developed to address areas of unmet medical need, finding inspiration in the World Health Organization’s Priority Medicines Report. Projects aim to advance trends in personalized medicines; to further R&D in areas of unmet medical need; and to address the regulatory context in hopes of speeding translation from research to innovation.
Ruxandra Draghia-Akli, Director, Health, DG Research and Innovation, European Commission:, said “IMI2 will carry on the collaborative spirit of IMI by bringing together the pharmaceutical industry, academic health research partners, small and medium enterprises, patients and regulators to advance scientific research and development for a healthy European society.”
More information on IMI 2 can be found here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
